We reflect on Dexcom's performance in 2025 and get up-to-date with news of their plans for a G8 sensor and international expansion.
Dexcom has confirmed it is developing its next CGM sensor, not surprisingly called G8, while also setting out a strategy to grow internationally. This follows strong financial performance in 2025.
The company has stressed that G8 is under active development but not expected to launch in the near term - although there are unconfirmed rumours that this may be accelerated as recently there have been a number of user issues with the G7.
Plans for the G8 are understood to involve focusing on advancing performance, wearability and future capabilities.
Dexcom’s CEO, Jake Leach, has described G8 as a “whole new wearable”, explaining that the next generation is being designed to improve accuracy, reliability and connectivity, while also reducing sensor size. Crucially, Leach has emphasised that innovation must go hand-in-hand with manufacturability, noting that Dexcom is engineering G8 so it can be produced at high scale and high quality, avoiding supply or reliability issues seen during earlier transitions.
Learning from challenges in 2025
Dexcom has acknowledged that 2025 presented operational challenges, including manufacturing scale-up pressures and the complexity of rolling out new technology across multiple markets at once. Company leadership has said these experiences are now shaping future decisions, with greater emphasis on stability, supply resilience and global scalability.
Strong financial results and international focus
Dexcom enters 2026 on the back of strong full-year 2025 results, reporting revenues of approximately £3.6 billion, representing a 16% year-on-year increase.
Looking ahead, Dexcom expects FY26 revenues to reach up to around £4.1 billion at the top end of guidance.
Leach, who officially became CEO on 1 January, said the growth was driven by expanding Dexcom’s user base:
“We did this by adding a record number of new patients to Dexcom.”
He added that the company exited 2025 with around 3.5 million active customers, representing an increase of over 20% compared with the end of 2024.
While Dexcom holds a strong position in the US CGM market, with a share of 44.7% in 2025, international markets remain a major opportunity. In regions such as Europe, Asia-Pacific and the Middle East & Africa, Dexcom trails market leader Abbott, highlighting the scale of the growth opportunity outside the US.
Speaking at the J.P. Morgan Healthcare Conference, Leach said:
“We've built our company based on leadership in the US, and we're now going to take that and apply it to the international markets, particularly our ability to open up access and coverage for people with CGM to unlock new opportunities that don’t exist today.”
A key part of this strategy will be the planned 2026 release of results from a large randomised controlled trial involving people with type 2 diabetes not using insulin. Leach said the data will “set the company up well” to support broader reimbursement and access internationally for this population.
The wider CGM market is forecast to continue expanding rapidly, with projected compound annual growth of 9.85%, reaching an estimated £12.2 billion global market value by 2035.
Timeline for G8
Dexcom has not announced a regulatory submission or launch date for G8. Public comments from leadership indicate the sensor remains at least a couple of years away, with the company continuing to prioritise optimisation of the G7 platform and international access in the meantime.
UK reassurance: Dexcom G6 remains available
For people using Dexcom's G6 CGM in the UK, Dexcom confirmed that it is not currently being withdrawn here.
Although Dexcom has announced plans to phase out G6 in the United States, with manufacturing there expected to end from July 2026, this transition is being managed on a country-by-country basis. In the UK, both Dexcom G6 and Dexcom G7 remain available, and there has been no announcement of an imminent withdrawal. This has also been confirmed by Prof Partha Kar, NHS T1 Diabetes Specialist for England.
Dexcom has stated that users in each market will receive advance notice before any changes to availability, allowing time for clinical discussion and transition planning where appropriate.
For now, UK users can continue using Dexcom G6 with confidence, while watching closely as Dexcom advances its international strategy and the longer-term development of its next-generation G8 sensor.
Expanding beyond CGM: Oura rings
Alongside its core CGM plans, Dexcom has also signalled its intention to expand into the wellness market, providing metabolic and health insights through a partnership with Oura,
Under the collaboration, Dexcom and Oura are working to integrate CGM data with Oura’s wearable metrics, such as sleep, activity, stress and recovery. The aim is to provide users with richer, context-aware insights into glucose trends, helping to explain how factors like sleep quality, illness, training load and daily stress interact with glucose levels.
The partnership is widely seen as part of Dexcom’s longer-term ambition to expand CGM beyond intensive insulin users, particularly into type 2 diabetes, metabolic health and preventative care markets. It also aligns with Dexcom’s emphasis on software, analytics and ecosystem partnerships as growth drivers alongside hardware innovation.
While timelines have not been confirmed, Dexcom has positioned the Oura partnership as a strategic foundation for future data-driven products, rather than a standalone consumer feature.
Leave a comment (all fields required). Please note, we are unable to respond to individual comments posted here.